C12N 2310/14
Interfering nucleic acids [na]
Official title: interfering nucleic acids [NA]
C12N2310/14 (Interfering nucleic acids [na]) appears on 7,098 US grants and 14,925 published applications in this corpus.
Search patents in C12N- Granted patents
- 7,098
- Published applications
- 14,925
- Assignees
- 3,306
- Inventors
- 19,831
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 8 |
| 2003 | 1 | 55 |
| 2004 | 2 | 153 |
| 2005 | 1 | 298 |
| 2006 | 13 | 265 |
| 2007 | 27 | 340 |
| 2008 | 33 | 345 |
| 2009 | 102 | 546 |
| 2010 | 212 | 649 |
| 2011 | 239 | 632 |
| 2012 | 330 | 612 |
| 2013 | 354 | 642 |
| 2014 | 402 | 629 |
| 2015 | 488 | 874 |
| 2016 | 462 | 893 |
| 2017 | 511 | 771 |
| 2018 | 548 | 782 |
| 2019 | 530 | 792 |
| 2020 | 491 | 761 |
| 2021 | 463 | 831 |
| 2022 | 428 | 838 |
| 2023 | 369 | 836 |
| 2024 | 370 | 869 |
| 2025 | 390 | 888 |
| 2026 | 332 | 616 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Method for optimized RIG-I ligands6 Oct 2026US 12,751,965 B2
- Methods and compositions for promoting survival and proliferation of endothelial cells and stimulating angiogenesis6 Oct 2026US 12,753,384 B2Cornell Research Foundation, Inc.
- Chemically modified oligonucleotides targeting bromodomain containing protein 4 (BRD4) for immunotherapy6 Oct 2026US 12,753,407 B2Phio Pharmaceuticals Corp.
- Double-stranded RNAi agents for targeting and regulating HBV gene expression, and a use thereof6 Oct 2026US 12,753,409 B2Hangzhou Tianlong Pharmaceutical Co., Ltd.
- FATS as a target for treating tumors and uses thereof6 Oct 2026US 12,753,410 B2Tianjin Medical University
- Methods and compositions for microbial delivery of double stranded rna8 Oct 2026US 2026/0305618 A1Rnaissance AG LLC
- Composition and Method for Topical Trans-spinal Delivery of Nucleic Acids and Small Molecules8 Oct 2026US 2026/0306414 A13P Biotechnologies, Inc.
- Modified adeno-associated virus vector and use thereof in treating neurological diseases8 Oct 2026US 2026/0306673 A1Genecombio Ltd.
- Extracellular vesicles8 Oct 2026US 2026/0308526 A1VivaZome Therapeutics Pty Ltd
- Apoe-activating noncoding rna (erna) and uses thereof8 Oct 2026US 2026/0308586 A1The J. David Gladstone Institutes, A Testamentary Trust Established Under the Will of J. David
Most cited
By later US patents
- Genetic inhibition by double-stranded RNA1,185US 6,506,559 B1Carnegie Institute of Washington · 2003
- RNA interference mediating small RNA molecules382US 7,056,704 B2MAX-PLANCK-GESELLSCHAFT zur FOERDERUNG der WISSENSCHAFTEN.e.V · 2006
- Lipid formulation340US 8,158,601 B2Alnylam Pharmaceuticals, Inc. · 2012
- Lipid formulations for nucleic acid delivery334US 8,058,069 B2Protiva Biotherapeutics, Inc. · 2011
- RNA interference mediating small RNA molecules333US 7,078,196 B2MAX-PLANCK-GESELLSCHAFT zur FOERDERUNG der WISSENSCHAFTEN.e.V · 2006